Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 9/20 | 0.65 |
| ▸ | JAK3 | P52333 | 9/20 | 0.65 |
| ▸ | PTK2 | Q05397 | 8/20 | 0.49 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.47 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.47 |
| ▸ | LCK | P06239 | 1/20 | 0.47 |
| ▸ | YES1 | P07947 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | BMP4 | P12644 | 1/20 | 0.47 |
| ▸ | SRC | P12931 | 1/20 | 0.47 |
| ▸ | FLT1 | P17948 | 1/20 | 0.47 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.47 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.47 |
| ▸ | ACVR1B | P36896 | 1/20 | 0.47 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.47 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.47 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.47 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2635534 | 0.79 | JAK2 (1.00) | JAK2JAK3PTK2 | |
| SCHEMBL3801663 | 0.77 | JAK2 (0.71) | JAK2JAK3PTK2 | |
| SCHEMBL20770534 | 0.69 | JAK2 (0.55) | JAK2JAK3PTK2BMPR1BPRKAB2 | |
| SCHEMBL15416890 | 0.69 | JAK2 (0.73) | JAK2JAK3PTK2LTA4H | |
| SCHEMBL25059331 | 0.67 | LTA4H (0.87) | LTA4HHRH3 | |
| SCHEMBL2635289 | 0.66 | JAK2 (1.00) | JAK2JAK3PTK2 | |
| SCHEMBL18837471 | 0.66 | LTA4H (0.84) | LTA4HHRH3 | |
| SCHEMBL1899201 | 0.65 | LTA4H (1.00) | LTA4HHRH3 | |
| SCHEMBL17799254 | 0.65 | KDR (0.80) | BMPR1BPRKAB2LCKYES1THRB | |
| SCHEMBL255201 | 0.64 | LTA4H (0.86) | LTA4HHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8633173-B2 | Preparation and uses of 1,2,4-triazolo [1,5a] pyridine derivatives | CEPHALON, INC (US) | 2014-01-21 | — | — | US | disclosed |
| US-20130296312-A1 | Preparation and Uses of 1,2,4-Triazolo [1,5a] Pyridine Derivatives | CEPHALON, INC. | 2013-11-07 | — | — | US | disclosed |
| US-8501936-B2 | Preparation and uses of 1,2,4-triazolo [1,5a] pyridine derivatives | CEPHALON, INC. (US) | 2013-08-06 | — | — | US | disclosed |
| EP-2438066-A2 | PREPARATION AND USES OF 1,2,4-TRIAZOLO [1,5a]PYRIDINE DERIVATIVES | Cephalon, Inc. (US) | 2012-04-11 | — | — | EP | disclosed |
| US-20100311693-A1 | Preparation and Uses of 1,2,4-Triazolo [1,5a] Pyridine Derivatives | CEPHALON, INC. (US) | 2010-12-09 | — | — | US | disclosed |
| WO-2010141796-A2 | PREPARATION AND USES OF 1,2,4-TRIAZOLO [1,5a] PYRIDINE DERIVATIVES | CEPHALON, INC. (US) | 2010-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130296312-A1 | Preparation and Uses of 1,2,4-Triazolo [1,5a] Pyridine Derivatives | JAK2, JAK1, JAK3 | JAK2 1/4885JAK3 3/4885PTK2 451/4885 |
| US-20100311693-A1 | Preparation and Uses of 1,2,4-Triazolo [1,5a] Pyridine Derivatives | CCNA1, CCNY, RB1 | JAK2 31/4885JAK3 175/4885PTK2 1114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.